The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

IDEAYA Biosciences Initiates Phase 1 Clinical Trial for Oncology Candidate IDE574

Key Facts

1IDEAYA Biosciences announced the enrollment of the first patient in a Phase 1 trial evaluating IDE574.

2IDE574 is a potential first-in-class dual inhibitor of KAT6/7 targeting multiple solid tumors including breast, prostate, and lung cancer.

3The company plans to present the preclinical profile of the drug at the AACR 2026 conference.

Create Free Account

IDEAYA Biosciences (NASDAQ: IDYA) has announced the enrollment of the first patient in its Phase 1 clinical trial evaluating IDE574. The drug is a potential first-in-class dual inhibitor of KAT6/7, designed to target various solid tumors including breast, prostate, and lung cancers. This milestone marks the transition of the oncology candidate from preclinical development to human testing to evaluate safety and efficacy. The trial aims to determine the initial therapeutic profile of the compound in patients with specific genetic markers. IDEAYA plans to present the comprehensive preclinical profile of IDE574 at the AACR 2026 conference. The commencement of human trials represents a significant step forward for the company's precision medicine pipeline. This development is a key clinical milestone, although it remains in the early stages of the regulatory approval process.